



*vaccines*



an Open Access Journal by MDPI

## Extracellular Vesicles and Nanoparticles: Mechanisms of Cellular Communication, Disease Regulation, and Biomarker Discovery

Guest Editors:

**Dr. Daniel O. Pinto**

Walter Reed Army Institute of  
Research, Silver Spring, MD  
20910, USA

**Dr. Elke S. Bergmann-Leitner**

Department of Primary  
Appointment, School of  
Medicine, Silver Spring, MD  
20910, USA

Deadline for manuscript  
submissions:

**closed (30 November 2022)**

### Message from the Guest Editors

Extracellular vesicles (EVs) are increasingly identified as important players in the progression of disease by enhancing the underlying mechanisms of infection. Similarly, EVs may serve as transporters of biological “messages” allowing for the evasion of the immune system and targeting of specific cells. The overall goal of this Special Issue is to bring together expertise from the fields of infectious diseases, cell-to-cell communication, immunology, CNS, diagnostics, biomarker discovery, and nanoparticle technology to elucidate the role of EVs in the interphase between the immune system, central nervous system (CNS), and disease progression. Based on your expertise, we invite you to contribute with an original report, original observation or review, to highlight (i) mechanisms of EV biogenesis, (ii) immune pathways affected by EVs, (iii) mechanisms of EV invasion into the CNS, (iv) nanoparticle synthesis or use in diagnostics of disease, and (v) recent advances in EV-based therapeutics.



[mdpi.com/si/77836](https://mdpi.com/si/77836)

# Special Issue



an Open Access Journal by MDPI

## Editor-in-Chief

### **Prof. Dr. Ralph A. Tripp**

Department of Infectious  
Diseases, College of Veterinary  
Medicine, University of Georgia,  
Athens, GA 30602-7387, USA

## Message from the Editor-in-Chief

*Vaccines* (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

## Author Benefits

**Open Access:** free for readers, with **article processing charges (APC)** paid by authors or their institutions.

**High Visibility:** indexed within **Scopus**, **SCIE (Web of Science)**, **PubMed**, **PMC**, **Embase**, **CAPus / SciFinder**, and **other databases**.

**Journal Rank:** JCR - Q1 (*Immunology*) / CiteScore - Q1 (*Pharmacology (medical)*)

## Contact Us

---

*Vaccines* Editorial Office  
MDPI, St. Alban-Anlage 66  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/vaccines](http://mdpi.com/journal/vaccines)  
[vaccines@mdpi.com](mailto:vaccines@mdpi.com)